These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 36867327)

  • 1. Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities.
    Dewilde S; Qi CZ; Phillips G; Iannazzo S; Janssen MF
    Adv Ther; 2023 Apr; 40(4):1818-1829. PubMed ID: 36867327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
    Saccà F; Barnett C; Vu T; Peric S; Phillips GA; Zhao S; Qi CZ; Gelinas D; Chiroli S; Verschuuren JJGM
    J Neurol; 2023 Apr; 270(4):2096-2105. PubMed ID: 36598575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis.
    Barnett C; Bril V; Bayoumi AM
    Eur J Neurol; 2019 Mar; 26(3):452-459. PubMed ID: 30315714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
    van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
    Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
    Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
    Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies.
    Dewilde S; Phillips G; Paci S; De Ruyck F; Tollenaar NH; Janssen MF
    Adv Ther; 2023 Oct; 40(10):4377-4394. PubMed ID: 37490259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
    Meregaglia M; Borsoi L; Cairns J; Tarricone R
    Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG.
    Dewilde S; Philips G; Paci S; Beauchamp J; Chiroli S; Quinn C; Day L; Larkin M; Palace J; Berrih-Aknin S; Claeys KG; Muppidi S; Mantegazza R; Saccà F; Meisel A; Bassez G; Murai H; Janssen MF
    BMJ Open; 2023 Jan; 13(1):e066445. PubMed ID: 36720569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in amyotrophic lateral sclerosis using EQ-5D-5L.
    Wei QQ; Hou Y; Chen Y; Ou R; Cao B; Zhang L; Yang T; Shang H
    Health Qual Life Outcomes; 2021 Jul; 19(1):181. PubMed ID: 34284776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
    J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriateness of the EQ-5D-5L in capturing health-related quality of life in individuals with transfusion-dependent β-thalassemia: a mixed methods study.
    Boateng-Kuffour A; Skrobanski H; Drahos J; Kohli P; Forster K; Acaster S; Pakbaz Z; Li N; Williams K
    Health Qual Life Outcomes; 2024 Jul; 22(1):54. PubMed ID: 38992661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
    Xie J; Wang Y; Xu Y; Fine JT; Lam J; Garrison LP
    J Med Econ; 2022; 25(1):51-58. PubMed ID: 34907813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
    McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
    Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EQ-5D-5L and SF-6Dv2 health utilities scores of diffuse large B-cell lymphoma patients in China.
    Li M; Fang B; Gu H; Jiang Y
    Health Qual Life Outcomes; 2024 Sep; 22(1):80. PubMed ID: 39300432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L.
    Martin A; Meads D; Griffiths AW; Surr CA
    Value Health; 2019 Dec; 22(12):1417-1426. PubMed ID: 31806199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-Related Quality of Life (HRQoL) Using EQ-5D-5L: Value Set Derived for Indian Breast Cancer Cohort.
    Wadasadawala T; Mohanty SK; Sen S; Khan PK; Pimple S; Mane JV; Sarin R; Gupta S; Parmar V
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1199-1207. PubMed ID: 37116141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients.
    Wang P; Zhang B; Yin J; Xi J; Tan Y; Gao F; Zeng F; Chang T; Zhou H; Liang H; Zhao Z; Yang H; Zhao C; Huang S
    Front Neurol; 2024; 15():1407418. PubMed ID: 38966082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
    Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
    Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.